News
-
ACLA Statement on Medicare Reimbursement Rate For Serologic Testing
WASHINGTON, D.C. – Following the release by the Centers for Medicare and Medicaid Services (CMS) of a reimbursement rate of $42.13 for the most commonly-performed COVID-19 serologic tests, ACLA President Julie Khani released the following statement: “We applaud CMS’ release of a Medicare reimbursement rate that will encourage a broad cross section of laboratories to rapidly scale up capacity for accurate and reliable serologicContinue Reading »... -
ACLA Statement on HEROES Act
WASHINGTON, D.C. — Following the introduction of the ‘‘Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act” ACLA President Julie Khani issued the following statement: “ACLA is currently reviewing the HEROES Act. As noted in our letter to Secretary Azar last month, direct federal funding for laboratories performing COVID-19 testing is critical to achieve our nation’s testing goals. As labs across the country plan for the large capital expensesContinue Reading »... -
ACLA Statement on Expanding Access to Testing
WASHINGTON, D.C. — Following the Trump Administration’s announcements today on expanding access to testing, ACLA President Julie Khani released the following statement: “After scaling up to meet an unprecedented demand for testing, ACLA members have performed nearly five million tests for COVID-19. By expanding the availability of specimen collection materials, such as swabs and transport media, the actions announced by the White House today will help states takeContinue Reading »... -
ACLA Statement on Support Necessary For Laboratories
WASHINGTON, D.C. — Following ongoing developments related to COVID-19 testing and response, ACLA President Julie Khani issued the following statement: “Labs are not scaling back. We’re ramping up. ACLA members are investing in additional high-throughput testing platforms, retraining staff, and working to anticipate the supply challenges we’ll face down the road. During ACLA’s first meeting with the White House Coronavirus Task Force on March 4, weContinue Reading »... -
ACLA Statement on FDA’s Revised Policy for Serologic Tests
WASHINGTON, D.C. – Following the revised policy on serologic testing announced today by the Food and Drug Administration, ACLA President Julie Khani issued the following statement: “ACLA is reviewing the latest announcement by the FDA. We commend the agency for its continued diligence in evaluating the available data regarding testing options and implementing policies that promote the public’s health. It is essential that patients and clinicians canContinue Reading »... -
ACLA Serologic Testing White Paper
... -
No stranger to serving communities ravaged by an epidemic, Tennessee-based Aegis Sciences sets its sights on a new challenge
Every day, ACLA members are working around the clock to deliver accurate, reliable testing for communities across the country. Headquartered in Tennessee, Aegis Sciences Corporation, a leading health care company providing clinically innovative medication compliance testing and consulting services to providers, has joined the industry-wide effort to combat the COVID-19 pandemic. Known for their leadership in the fight against the opioid epidemic, Aegis quicklyContinue Reading »... -
ACLA Letter to HHS on PHSSEF Direct COVID19 Test Funding
... -
ACLA Statement on White House Meeting
WASHINGTON, D.C. – Following today’s meeting at the White House, ACLA President Julie Khani issued the following statement: “ACLA appreciated the opportunity to meet today with President Trump, Vice President Pence and other members of the White House Coronavirus Task Force. Representing the backbone of our nation’s testing response, ACLA members have now performed 3.2 million tests and remain focused on continuing to increaseContinue Reading »... -
In Tennessee and across the country, a calling to serve patients in need
This Laboratory Professionals Week, we’re taking a moment to thank laboratory researchers, technicians, administrative staff and medical officers who are going above and beyond the call of duty to serve patients during the COVID-19 pandemic. Today, ACLA is shining a light on Cyndi, a manager at Aegis Sciences who helped bring up new tests to meet the needs of patients in Tennessee. Cyndi is partContinue Reading »...
